APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. [electronic resource]
Producer: 20190625Description: 1167-1176 p. digitalISSN:- 1538-8514
- Animals
- Antineoplastic Agents -- pharmacology
- BRCA1 Protein -- deficiency
- BRCA2 Protein -- deficiency
- Breast Neoplasms -- genetics
- Cell Line, Tumor
- DNA Damage -- drug effects
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- genetics
- Female
- Humans
- Imidazoles -- pharmacology
- Phenanthrolines -- pharmacology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.